On the public citation graph
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
0 signed · 879 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/s10549-017-4518-8openalex-snapshot
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
inferredcites →https://doi.org/10.1007/s10549-017-4523-yopenalex-snapshot
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
inferredcites →https://doi.org/10.1016/s1470-2045(15)00613-0openalex-snapshot
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
inferredcites →https://doi.org/10.1056/nejmoa1607303openalex-snapshot
Palbociclib and Letrozole in Advanced Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1609709openalex-snapshot
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
inferredcites →https://doi.org/10.1093/annonc/mdw435.03openalex-snapshot
breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)
inferredcites →https://doi.org/10.1126/scitranslmed.aac7551openalex-snapshot
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-1029openalex-snapshot
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.1020openalex-snapshot
Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.2440379openalex-extracted
The Future of Forced Regime Change and Democracy
inferred← citeshttps://doi.org/10.2139/ssrn.4758645openalex-extracted
Ribociclib Induced Liver Injury in a Patient with Metastatic Breast Cancer, a Case Report
inferred← citeshttps://doi.org/10.3897/pharmacia.72.e144998zenodo-depositor-declared
Effect of multi-strain probiotics supplementation on chemotherapy-related side effects among patients with breast cancer: A pilot trial
inferred← citeshttps://doi.org/10.3897/pharmacia.73.e190655zenodo-depositor-declared
Effectiveness of ribociclib in metastatic breast cancer in one hospital in Bulgaria—results from real-world clinical practice
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.20312openalex-snapshot
Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.56170openalex-snapshot
Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.5460openalex-snapshot
Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer—Is Not Worse Good Enough?
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.3428openalex-snapshot
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.4301openalex-snapshot
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2025.3687openalex-snapshot
600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ ERBB2 -Negative Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1002/9783527826872.ch9openalex-snapshot
The Discovery of Kisqali ® (Ribociclib): A CDK 4/6 Inhibitor for the Treatment of HR +/ HER 2− Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1002/bcp.70265openalex-snapshot
Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database
inferred← citeshttps://doi.org/10.1002/cai2.143openalex-snapshot
Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer
inferred← citeshttps://doi.org/10.1002/cai2.46openalex-snapshot
Advances in medical treatment of breast cancer in 2022
inferred← citeshttps://doi.org/10.1002/cai2.70032openalex-snapshot
Guidelines for the Diagnosis and Treatment of Advanced Breast Cancer in China (2024 Edition)
inferred← citeshttps://doi.org/10.1002/cam4.2780openalex-snapshot
Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer
inferred← citeshttps://doi.org/10.1002/cam4.5827openalex-snapshot
Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10‐year, single‐center, real‐world study of 67 cases
inferred← citeshttps://doi.org/10.1002/cam4.6762openalex-snapshot
Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor‐positive, HER2 ‐negative metastatic breast cancer: A real‐world multicenter study
inferred← citeshttps://doi.org/10.1002/cam4.72224openalex-snapshot
Timing and Patterns of Relapse‐Related Events Following Adjuvant CDK4 /6 Inhibitors Combined With Endocrine Therapy in Patients With HR ‐Positive, HER2 ‐Negative Early Breast Cancer
inferred← citeshttps://doi.org/10.1002/cncr.32631openalex-snapshot
The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: A population‐based study in British Columbia from 2003 to 2013
inferred← citeshttps://doi.org/10.1002/cncr.32931openalex-snapshot
Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies
inferred← citeshttps://doi.org/10.1002/cncr.33650openalex-snapshot
Adjuvant cyclin‐dependent kinase 4/6 inhibition in hormone receptor–positive breast cancer: One Monarch to rule them all?
inferred← citeshttps://doi.org/10.1002/cncr.35174openalex-snapshot
Real‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis
inferred← citeshttps://doi.org/10.1002/cnr2.1308openalex-snapshot
Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
inferred← citeshttps://doi.org/10.1002/cpdd.853openalex-snapshot
Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin‐Dependent Kinase 4/6 Inhibitor, in Healthy Subjects
inferred← citeshttps://doi.org/10.1002/ddr.70354openalex-snapshot
Alternative Splicing in Cyclin‐Dependent Kinase 4/6 Inhibitor Resistance in Estrogen Receptor‐Positive Breast Cancer
inferred← citeshttps://doi.org/10.1002/hep.30704openalex-snapshot
Dependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity
inferred← citeshttps://doi.org/10.1002/iid3.70442openalex-snapshot
Predictive Role of Serum Inflammatory Markers in Metastatic Luminal A/B Breast Cancers Receiving CDK‐4/6 Inhibitors Therapy
inferred← citeshttps://doi.org/10.1002/ijc.33959openalex-snapshot
Palbociclib plus endocrine therapy significantly enhances overall survival of HR +/ HER2 − metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study
inferred← citeshttps://doi.org/10.1002/ijc.34570openalex-snapshot
The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status
inferred← citeshttps://doi.org/10.1002/ijc.35296openalex-snapshot
Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR ‐positive/ HER2 ‐negative metastatic breast cancer with real‐world data from the OPAL registry
inferred← citeshttps://doi.org/10.1002/ijc.70433openalex-snapshot
Prediction of dose reductions and impact of reduced starting doses of CDK4 /6i on effectiveness in HR ‐positive/ HER2 ‐negative metastatic breast cancer: Real‐world data from the OPAL registry
inferred← citeshttps://doi.org/10.1002/jcph.1825openalex-snapshot
Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment
inferred← citeshttps://doi.org/10.1002/jcph.2310openalex-snapshot
Quantitative Assessment of Ribociclib Exposure–Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1002/jms.4984openalex-snapshot
Simple and rapid quantification of ribociclib in rat plasma by protein precipitation and LC‐MS/MS: An application to pharmacokinetics of ribociclib nanoparticles in rats
inferred← citeshttps://doi.org/10.1002/mco2.181openalex-snapshot
Small molecule inhibitors targeting the cancers
inferred← citeshttps://doi.org/10.1002/mco2.70373openalex-snapshot
Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research
inferred← citeshttps://doi.org/10.1002/mco2.70404openalex-snapshot
Breast Cancer: Molecular Pathogenesis and Targeted Therapy
inferred← citeshttps://doi.org/10.1002/med.21856openalex-snapshot
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline
inferred← citeshttps://doi.org/10.1002/path.6078openalex-snapshot
CDK4 /6 inhibitor modulating active and quiescent intestinal stem cells for prevention of chemotherapy‐induced diarrhea
inferred← citeshttps://doi.org/10.1002/phar.70149openalex-snapshot
Thrombosis Across Female‐Specific Malignancies: From Chemotherapy‐Driven Risk to Prophylaxis and Drug Interactions
inferred← citeshttps://doi.org/10.1002/prp2.599openalex-snapshot
An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
inferred← citeshttps://doi.org/10.1007/16833_2022_38openalex-snapshot
A Hormone Immunotherapy (HIT) Combination in Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-16792-9_21openalex-snapshot
Breast Cancer in Older Women
inferred← citeshttps://doi.org/10.1007/978-3-030-16792-9_30openalex-snapshot
Treatment of Metastatic Breast Cancer: Endocrine Therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-16792-9_51openalex-snapshot
Systemic Treatment Drugs/Regimens and Dose Modifications
inferred← citeshttps://doi.org/10.1007/978-3-030-23417-1_27openalex-snapshot
Neurological Complications of Targeted Therapies
inferred← citeshttps://doi.org/10.1007/978-3-030-24762-1_12openalex-snapshot
Management of Advanced Breast Cancer in Young Women: What’s New in Systemic Treatment
inferred← citeshttps://doi.org/10.1007/978-3-030-67123-5_21openalex-snapshot
Cardiovascular Oncologic Emergencies
inferred← citeshttps://doi.org/10.1007/978-3-031-33602-7_12openalex-snapshot
New Concepts in Cardio-Oncology
inferred← citeshttps://doi.org/10.1007/978-3-031-70875-6_23openalex-snapshot
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-032-14420-1_8openalex-snapshot
Borderline Ovarian Tumours and Low-Grade Serous Carcinoma
inferred← citeshttps://doi.org/10.1007/978-3-319-57901-6_16openalex-snapshot
Neurological Complications of Targeted Therapies
inferred← citeshttps://doi.org/10.1007/978-3-319-96947-3_24openalex-snapshot
Endocrine Therapy of Metastatic Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-96947-3_27openalex-snapshot
Systemic Treatment Drugs and Regimens
inferred← citeshttps://doi.org/10.1007/978-3-319-99350-8_9openalex-snapshot
Endocrine Therapy in Clinical Practice
inferred← citeshttps://doi.org/10.1007/s00129-017-4111-6openalex-snapshot
Endokrine Therapie beim metastasierten Mammakarzinom
inferred← citeshttps://doi.org/10.1007/s00129-019-4415-9openalex-snapshot
Endokrine Therapie des metastasierten Mammakarzinoms
inferred← citeshttps://doi.org/10.1007/s00129-021-04792-7openalex-snapshot
Endokrine Kombinationstherapien beim lokal fortgeschrittenen, metastasierten Mammakarzinom – zusammen besser als allein
inferred← citeshttps://doi.org/10.1007/s00129-023-05080-2openalex-snapshot
Das metastasierte Mammakarzinom – ein Überblick über die Therapiestandards
inferred← citeshttps://doi.org/10.1007/s00129-025-05358-7openalex-snapshot
Metastasiertes hormonrezeptorpositives Mammakarzinom – die Qual der Wahl
inferred← citeshttps://doi.org/10.1007/s00262-026-04480-2openalex-snapshot
R-5780, a SagA-engineered Lactococcus lactis, is a safe oral synthetic-biology microbial therapy that potentiates PD-1 blockade
inferred← citeshttps://doi.org/10.1007/s00280-021-04254-wopenalex-snapshot
Cardiovascular toxicity of breast cancer treatment: an update
inferred← citeshttps://doi.org/10.1007/s00428-024-03856-yopenalex-snapshot
Neuroendocrine neoplasms of the breast: a review of literature
inferred← citeshttps://doi.org/10.1007/s00432-021-03588-5openalex-snapshot
Clinical application of circulating tumor DNA in breast cancer
inferred← citeshttps://doi.org/10.1007/s00432-023-04723-0openalex-snapshot
Characterization of clinicopathological features, treatment practices, and outcomes among Finnish advanced breast cancer patients in real-life clinical practice
inferred← citeshttps://doi.org/10.1007/s00432-025-06336-1openalex-snapshot
Management of hepatotoxicity associated with CDK4/6 inhibitors and rechallenge strategies in metastatic hormone-positive, HER2-negative breast cancer
inferred← citeshttps://doi.org/10.1007/s00508-023-02254-9openalex-snapshot
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
inferred← citeshttps://doi.org/10.1007/s00508-025-02582-yopenalex-snapshot
Was kommt nach CDK4/6-Inhibition? Perspektiven beim fortgeschrittenen Mammakarzinom
inferred← citeshttps://doi.org/10.1007/s00520-024-08702-0openalex-snapshot
Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram
inferred← citeshttps://doi.org/10.1007/s00520-025-09625-0openalex-snapshot
Hepatotoxicity across CDK 4/6 inhibitors: a Narrative Review
inferred← citeshttps://doi.org/10.1007/s00761-019-00648-xopenalex-snapshot
Neue Entwicklungen der Systemtherapie maligner Erkrankungen
inferred← citeshttps://doi.org/10.1007/s00761-019-0574-5openalex-snapshot
Endokrine Therapie des metastasierten Mammakarzinoms
inferred← citeshttps://doi.org/10.1007/s10549-018-4769-zopenalex-snapshot
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
inferred← citeshttps://doi.org/10.1007/s10549-018-4901-0openalex-snapshot
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
inferred← citeshttps://doi.org/10.1007/s10549-019-05176-1openalex-snapshot
Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy
inferred← citeshttps://doi.org/10.1007/s10549-019-05190-3openalex-snapshot
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
inferred← citeshttps://doi.org/10.1007/s10549-019-05261-5openalex-snapshot
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
inferred← citeshttps://doi.org/10.1007/s10549-019-05349-yopenalex-snapshot
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy
inferred← citeshttps://doi.org/10.1007/s10549-020-05617-2openalex-snapshot
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors
inferred← citeshttps://doi.org/10.1007/s10549-021-06215-6openalex-snapshot
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s10549-021-06334-0openalex-snapshot
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
inferred← citeshttps://doi.org/10.1007/s10549-021-06382-6openalex-snapshot
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s10549-022-06543-1openalex-snapshot
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
inferred← citeshttps://doi.org/10.1007/s10549-023-06967-3openalex-snapshot
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s10549-023-07073-0openalex-snapshot
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer
inferred← citeshttps://doi.org/10.1007/s10549-023-07145-1openalex-snapshot
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
inferred← citeshttps://doi.org/10.1007/s10549-023-07226-1openalex-snapshot
The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s10549-024-07291-0openalex-snapshot
The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study
inferred← citeshttps://doi.org/10.1007/s10549-024-07316-8openalex-snapshot
Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study
inferred← citeshttps://doi.org/10.1007/s10549-024-07415-6openalex-snapshot
First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting
inferred← citeshttps://doi.org/10.1007/s10549-025-07879-0openalex-snapshot
Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors
inferred← citeshttps://doi.org/10.1007/s10549-025-07893-2openalex-snapshot
Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study
inferred← citeshttps://doi.org/10.1007/s10549-026-07931-7openalex-snapshot
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study
inferred← citeshttps://doi.org/10.1007/s10549-026-07939-zopenalex-snapshot
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial
inferred← citeshttps://doi.org/10.1007/s10549-026-08012-5openalex-snapshot
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study
inferred← citeshttps://doi.org/10.1007/s10549-026-08060-xopenalex-snapshot
Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018–2024
inferred← citeshttps://doi.org/10.1007/s11060-023-04276-9openalex-snapshot
Systematic review of the management of brain metastases from hormone receptor positive breast cancer
inferred← citeshttps://doi.org/10.1007/s11523-022-00913-xopenalex-snapshot
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
inferred← citeshttps://doi.org/10.1007/s11523-025-01137-5openalex-snapshot
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1007/s11523-026-01232-1openalex-snapshot
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
inferred← citeshttps://doi.org/10.1007/s11864-019-0651-4openalex-snapshot
The Role of CDK4/6 Inhibitors in Breast Cancer
inferred← citeshttps://doi.org/10.1007/s11864-019-0657-yopenalex-snapshot
QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics
inferred← citeshttps://doi.org/10.1007/s11864-024-01275-4openalex-snapshot
Oligometastatic Breast Cancer: Seeking the Cure by Redefining Stage IV Disease?
inferred← citeshttps://doi.org/10.1007/s11864-025-01310-yopenalex-snapshot
Novel Estrogen Receptor – Targeted Therapies in Hormone-Receptor Positive Breast Cancer
inferred← citeshttps://doi.org/10.1007/s11897-020-00486-8openalex-snapshot
Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer
inferred← citeshttps://doi.org/10.1007/s11912-020-00917-8openalex-snapshot
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
inferred← citeshttps://doi.org/10.1007/s11912-023-01393-6openalex-snapshot
Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1007/s11912-024-01540-7openalex-snapshot
CDK4/6 inhibitors: The Devil is in the Detail
inferred← citeshttps://doi.org/10.1007/s11912-025-01689-9openalex-snapshot
Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors
inferred← citeshttps://doi.org/10.1007/s11936-019-0738-zopenalex-snapshot
Cardiotoxicities of Modern Treatments in Breast Cancer
inferred← citeshttps://doi.org/10.1007/s12032-022-01779-9openalex-snapshot
Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study
inferred← citeshttps://doi.org/10.1007/s12094-018-02010-wopenalex-snapshot
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
inferred← citeshttps://doi.org/10.1007/s12094-021-02688-5openalex-snapshot
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
inferred← citeshttps://doi.org/10.1007/s12094-021-02766-8openalex-snapshot
Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s12094-023-03247-wopenalex-snapshot
Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2− breast cancer in Mexico
inferred← citeshttps://doi.org/10.1007/s12094-024-03399-3openalex-snapshot
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
inferred← citeshttps://doi.org/10.1007/s12094-026-04369-7openalex-snapshot
Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy
inferred← citeshttps://doi.org/10.1007/s12254-021-00718-0openalex-snapshot
Post San Antonio update—my top three abstracts!
inferred← citeshttps://doi.org/10.1007/s12282-022-01422-5openalex-snapshot
Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study
inferred← citeshttps://doi.org/10.1007/s12282-023-01505-xopenalex-snapshot
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
inferred← citeshttps://doi.org/10.1007/s12282-024-01641-yopenalex-snapshot
A genome-wide CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer
inferred← citeshttps://doi.org/10.1007/s12282-025-01713-7openalex-snapshot
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s12282-025-01779-3openalex-snapshot
Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer
inferred← citeshttps://doi.org/10.1007/s12325-020-01552-2openalex-snapshot
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
inferred← citeshttps://doi.org/10.1007/s12609-019-0308-0openalex-snapshot
Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer
inferred← citeshttps://doi.org/10.1007/s12609-022-00461-3openalex-snapshot
Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling
inferred← citeshttps://doi.org/10.1007/s12609-025-00606-0openalex-snapshot
Progress in Clinical Trials of CDK4/6 Inhibitors
inferred← citeshttps://doi.org/10.1007/s12672-025-02820-9openalex-snapshot
Drug treatment of breast cancer brain metastases: progress and challenges
inferred← citeshttps://doi.org/10.1007/s15013-019-1638-8openalex-snapshot
Mammakarzinom: neue Daten zu Ribociclib
inferred← citeshttps://doi.org/10.1007/s15015-018-4353-8openalex-snapshot
Mammakarzinom: CDK4/6-Hemmung auch nach zwei Jahren vorteilhaft
inferred← citeshttps://doi.org/10.1007/s40259-019-00382-1openalex-snapshot
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications
inferred← citeshttps://doi.org/10.1007/s40262-020-00930-xopenalex-snapshot
Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib
inferred← citeshttps://doi.org/10.1007/s40262-022-01206-2openalex-snapshot
Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials
inferred← citeshttps://doi.org/10.1007/s40262-023-01338-zopenalex-snapshot
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1007/s40264-023-01334-zopenalex-snapshot
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment
inferred← citeshttps://doi.org/10.1007/s40265-020-01394-wopenalex-snapshot
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1007/s40265-022-01781-5openalex-snapshot
Emerging Targeted Therapies for Early Breast Cancer
inferred← citeshttps://doi.org/10.1007/s40265-024-02144-yopenalex-snapshot
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
inferred← citeshttps://doi.org/10.1007/s40273-023-01245-yopenalex-snapshot
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
inferred← citeshttps://doi.org/10.1007/s40487-018-0090-6openalex-snapshot
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
inferred← citeshttps://doi.org/10.1007/s40801-022-00327-1openalex-snapshot
Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib
inferred← citeshttps://doi.org/10.1007/s40801-023-00391-1openalex-snapshot
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice
inferred← citeshttps://doi.org/10.1007/s41974-022-00226-xopenalex-snapshot
Kongress-Update zum Mammakarzinom
inferred← citeshttps://doi.org/10.1016/b978-0-12-821666-8.00069-4openalex-snapshot
The effects of anticancer therapies on bone metastases in breast cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-95116-6.00004-9openalex-snapshot
Somatic mutation: Pharmacogenomics in oncology care
inferred← citeshttps://doi.org/10.1016/b978-0-443-13825-6.00375-7openalex-snapshot
Hormonal treatment of breast cancer
inferred← citeshttps://doi.org/10.1016/b978-0-443-23932-8.00022-4openalex-snapshot
Palbociclib, ribociclib, and abemaciclib: potent and selective CDK4/6 inhibitors for the treatment of breast cancer
inferred← citeshttps://doi.org/10.1016/j.annonc.2020.12.003openalex-snapshot
SOLAR1s: alpelisib returns to earth?
inferred← citeshttps://doi.org/10.1016/j.annonc.2020.12.013openalex-snapshot
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
inferred← citeshttps://doi.org/10.1016/j.annonc.2021.09.015openalex-snapshot
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
inferred← citeshttps://doi.org/10.1016/j.annonc.2021.10.214openalex-snapshot
Adjuvant abemaciclib for high-risk breast cancer: the story continues
inferred← citeshttps://doi.org/10.1016/j.annonc.2022.05.006openalex-snapshot
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer
inferred← citeshttps://doi.org/10.1016/j.annonc.2023.08.011openalex-snapshot
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
inferred← citeshttps://doi.org/10.1016/j.annonc.2023.11.003openalex-snapshot
Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− metastatic breast cancer?
inferred← citeshttps://doi.org/10.1016/j.annonc.2024.04.013openalex-snapshot
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
inferred← citeshttps://doi.org/10.1016/j.annonc.2025.03.023openalex-snapshot
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
inferred← citeshttps://doi.org/10.1016/j.apsb.2026.07.050openalex-snapshot
Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR+/HER2– advanced breast cancer
inferred← citeshttps://doi.org/10.1016/j.bbcan.2022.188830openalex-snapshot
ESR1 activating mutations: From structure to clinical application
inferred← citeshttps://doi.org/10.1016/j.bcp.2022.115209openalex-snapshot
Targeted therapy for breast cancer: An overview of drug classes and outcomes
inferred← citeshttps://doi.org/10.1016/j.breast.2018.10.001openalex-snapshot
Targeting CDK4/6 pathways and beyond in breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2018.11.008openalex-snapshot
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value
inferred← citeshttps://doi.org/10.1016/j.breast.2019.05.001openalex-snapshot
Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity
inferred← citeshttps://doi.org/10.1016/j.breast.2019.10.016openalex-snapshot
Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
inferred← citeshttps://doi.org/10.1016/j.breast.2020.09.008openalex-snapshot
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
inferred← citeshttps://doi.org/10.1016/j.breast.2021.02.015openalex-snapshot
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study
inferred← citeshttps://doi.org/10.1016/j.breast.2021.05.008openalex-snapshot
The role of CDK4/6 inhibitors in early breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2021.07.002openalex-snapshot
Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
inferred← citeshttps://doi.org/10.1016/j.breast.2021.10.001openalex-snapshot
Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2021.12.008openalex-snapshot
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2022.09.006openalex-snapshot
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
inferred← citeshttps://doi.org/10.1016/j.breast.2022.09.009openalex-snapshot
Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
inferred← citeshttps://doi.org/10.1016/j.breast.2022.10.005openalex-snapshot
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
inferred← citeshttps://doi.org/10.1016/j.breast.2023.01.005openalex-snapshot
How I treat HER2-low advanced breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2024.103859openalex-snapshot
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2024.103863openalex-snapshot
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
inferred← citeshttps://doi.org/10.1016/j.breast.2025.103875openalex-snapshot
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2025.104448openalex-snapshot
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis
inferred← citeshttps://doi.org/10.1016/j.breast.2025.104485openalex-snapshot
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists
inferred← citeshttps://doi.org/10.1016/j.breast.2025.104527openalex-snapshot
BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study
inferred← citeshttps://doi.org/10.1016/j.breast.2025.104568openalex-snapshot
Baseline neutrophil-lymphocyte ratio (NLR) predicts toxicity and survival in HR+/HER-2 breast cancer patients treated with CDK4/6 inhibitors
inferred← citeshttps://doi.org/10.1016/j.breast.2025.104607openalex-snapshot
Improving survival outcomes of people with ABC: a global expert review and call-to-action for 2025–2035 (Goal 1)
inferred← citeshttps://doi.org/10.1016/j.breast.2026.104692openalex-snapshot
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
inferred← citeshttps://doi.org/10.1016/j.breast.2026.104769openalex-snapshot
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
inferred← citeshttps://doi.org/10.1016/j.breast.2026.104817openalex-snapshot
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study
inferred← citeshttps://doi.org/10.1016/j.bulcan.2021.04.007openalex-snapshot
Place des inhibiteurs de kinases dépendantes des cyclines 4/6 dans la prise en charge du cancer du sein avancé
inferred← citeshttps://doi.org/10.1016/j.bulcan.2021.12.009openalex-snapshot
Actualités 2021 sur le cancer du sein localement avancé ou métastatique RH+/HER2−
inferred← citeshttps://doi.org/10.1016/j.bulcan.2023.01.002openalex-snapshot
2022 : nouvelles pratiques thérapeutiques en oncologie mammaire
inferred← citeshttps://doi.org/10.1016/j.canlet.2026.218737openalex-snapshot
Membrane bionic supramolecular nanomaterials for co-delivered of ribociclib and PEG10 siRNA for targeted therapy in breast cancer
inferred← citeshttps://doi.org/10.1016/j.celrep.2021.110278openalex-snapshot
Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors
inferred← citeshttps://doi.org/10.1016/j.celrep.2023.112314openalex-snapshot
Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance
inferred← citeshttps://doi.org/10.1016/j.clbc.2019.02.004openalex-snapshot
Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor–Positive/Human Epidermal Receptor 2–Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs
inferred← citeshttps://doi.org/10.1016/j.clbc.2019.06.011openalex-snapshot
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1016/j.clbc.2019.06.017openalex-snapshot
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2− Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.clbc.2021.07.013openalex-snapshot
Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature
inferred← citeshttps://doi.org/10.1016/j.clbc.2021.08.002openalex-snapshot
Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?
inferred← citeshttps://doi.org/10.1016/j.clbc.2021.08.007openalex-snapshot
The Effects of HER2 on CDK4/6 Activity in Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.clbc.2021.10.007openalex-snapshot
The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC
showing the first 200 of 869 · page through all 869
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.